Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Study on sortilin and prostate cancer

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on May 08, 2022 11:30pm

169 Views

Post# 34665902

RE:RE:RE:Study on sortilin and prostate cancer

This means sortilin is low in DU145 and PC3 prostate cancer cell lines in vitro. We already know that sortilin is not overexpressed in 100% of a given cancer type. So it is irrelevant in itself. Maybe they will not test for sortilin overexpression in melanoma or other cancer type where sortilin is overexpressed in 90%+ of this cancer type, but in cancers like prostate or other where the overoxpression is in 40-50% of the cases, they will have to test overexpression from biopsies.